Cite
HARVARD Citation
Mercuri, E. et al. (2022). Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet neurology. 21 (1), pp. 42-52. [Online].